ATE109982T1 - Prostaglandin-lipid-formulierungen. - Google Patents

Prostaglandin-lipid-formulierungen.

Info

Publication number
ATE109982T1
ATE109982T1 AT88401235T AT88401235T ATE109982T1 AT E109982 T1 ATE109982 T1 AT E109982T1 AT 88401235 T AT88401235 T AT 88401235T AT 88401235 T AT88401235 T AT 88401235T AT E109982 T1 ATE109982 T1 AT E109982T1
Authority
AT
Austria
Prior art keywords
prostaglandin
transmembrane
liposomes
lipid formulations
gradient
Prior art date
Application number
AT88401235T
Other languages
English (en)
Inventor
Robert P Lenk
Michelle M Tomsho
Robert L Suddith
Robert J Klimchak
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ATE109982T1 publication Critical patent/ATE109982T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT88401235T 1987-05-22 1988-05-20 Prostaglandin-lipid-formulierungen. ATE109982T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5330587A 1987-05-22 1987-05-22

Publications (1)

Publication Number Publication Date
ATE109982T1 true ATE109982T1 (de) 1994-09-15

Family

ID=21983292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88401235T ATE109982T1 (de) 1987-05-22 1988-05-20 Prostaglandin-lipid-formulierungen.

Country Status (12)

Country Link
US (1) US5082664A (de)
EP (1) EP0292403B1 (de)
KR (1) KR970005171B1 (de)
AT (1) ATE109982T1 (de)
AU (1) AU617678B2 (de)
CA (1) CA1323838C (de)
DE (1) DE3851090T2 (de)
ES (1) ES2058317T3 (de)
FI (1) FI95199C (de)
PT (1) PT87545B (de)
WO (1) WO1988009170A1 (de)
ZA (1) ZA883653B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5811118A (en) * 1987-05-22 1998-09-22 The Liposome Company, Inc. Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
US5591446A (en) * 1989-04-04 1997-01-07 Beiersdorf, A.G. Methods and agents for the prophylaxis of atopy
DE3910761A1 (de) * 1989-04-04 1990-10-11 Bodo Dr Med Melnik Mittel zur atopie-prophylaxe
DK0391218T3 (da) * 1989-04-04 1996-07-29 Beiersdorf Ag Middel til forebyggelse af atopi
JPH0395118A (ja) * 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
US5882678A (en) * 1990-01-12 1999-03-16 The Liposome Co, Inc. Interdigitation-fusion liposomes containing arachidonic acid metabolites
DE69228332T2 (de) * 1991-05-07 1999-09-16 The Liposome Co.,Inc. Liposomale Prostaglandinformulierungen
DE4125255A1 (de) * 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
US6005100A (en) * 1992-12-02 1999-12-21 Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo Trehalose composition for prolonging product shelf life
JP3168550B2 (ja) * 1992-12-02 2001-05-21 株式会社林原生物化学研究所 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品
AU676906B2 (en) * 1993-04-02 1997-03-27 Transave, Inc. Method of producing liposomes
WO1995001777A1 (en) 1993-07-08 1995-01-19 The Liposome Company, Inc. Method of controlling the size of liposomes
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
NZ273752A (en) * 1993-10-27 1998-03-25 Upjohn Co Stabilised prostaglandin e1 lyophilisate using tertiary butanol and lactose carriers
CA2175896A1 (en) * 1993-11-04 1995-05-11 Marc J. Ostro Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
DK0729352T3 (da) * 1993-11-16 1999-09-20 Liposome Co Inc Interdigiteringsfusionsliposomer indeholdende arachidonsyremetabolitter
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
WO1996009037A1 (en) * 1994-09-23 1996-03-28 The Liposome Company, Inc. Method of producing a lyophilized liposome product
US5718917A (en) * 1995-12-15 1998-02-17 Harvard Scientific Corporation PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US6447800B2 (en) * 1996-01-18 2002-09-10 The University Of British Columbia Method of loading preformed liposomes using ethanol
US5980551A (en) * 1997-02-07 1999-11-09 Endovasc Ltd., Inc. Composition and method for making a biodegradable drug delivery stent
US6001333A (en) * 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
US6019999A (en) * 1997-12-03 2000-02-01 Miller; David F. Process for making liposomal ion-exchange whey protein and products thereof
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
KR101411758B1 (ko) * 2006-09-05 2014-06-25 큐피가부시키가이샤 프로스태글란딘 지방 에멀젼, 이의 제조 방법, 그 에멀젼의안정화 방법 및 에멀젼화제
US20090035725A1 (en) * 2007-08-02 2009-02-05 Ondine International, Ltd. Photodisinfection of oral cavity
EP2331070A1 (de) * 2008-09-26 2011-06-15 Phares Pharmaceutical Research N.V. Verfahren zur solubilisierung von biologisch wirksamen verbindungen
US9835618B1 (en) * 2009-02-06 2017-12-05 Los Alamos National Security, Llc Discovery, detection and use of biomarkers
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
SG187770A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9962393B1 (en) * 2015-06-21 2018-05-08 Angiosoma Research, Inc. Method for treating vascular disease by administering a liposomal prostaglandin composition
AU2019266171B2 (en) * 2018-05-07 2021-10-28 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of treprostinil
EP4312536A1 (de) 2021-04-01 2024-02-07 Vestaron Corporation Liposomformulierungen zur pestizidabgabe und verfahren zur herstellung und verwendung davon

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2274122A1 (fr) * 1974-06-07 1976-01-02 Cgr Mev Procede de centrage d'un faisceau de balayage a rayonnement ionisant et dispositif permettant la mise en oeuvre de ce procede
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
EP0153955A1 (de) * 1983-09-06 1985-09-11 Health Research, Inc. Verfahren zum verabreichen von liposomen zum herabsetzen der toxizität eines antitumor-arzneimittels
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
CA1264668A (en) * 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
JPS61100518A (ja) * 1984-10-22 1986-05-19 Ono Pharmaceut Co Ltd ジミリストイルホスフアチジルコリンを主成分とする凍結乾燥されたリポゾ−ム製剤
EP0231261B1 (de) * 1985-07-05 1994-04-06 The Liposome Company, Inc. Multilamellare liposome mit verbesserter einschliessungswirkung

Also Published As

Publication number Publication date
KR890701093A (ko) 1989-12-19
PT87545A (pt) 1989-05-31
CA1323838C (en) 1993-11-02
HK1007496A1 (en) 1999-04-16
AU617678B2 (en) 1991-12-05
EP0292403A2 (de) 1988-11-23
ZA883653B (en) 1989-03-29
ES2058317T3 (es) 1994-11-01
EP0292403B1 (de) 1994-08-17
EP0292403A3 (en) 1988-12-21
FI895554A0 (fi) 1989-11-21
DE3851090T2 (de) 1995-01-12
WO1988009170A1 (en) 1988-12-01
PT87545B (pt) 1992-12-31
KR970005171B1 (ko) 1997-04-14
US5082664A (en) 1992-01-21
FI95199C (fi) 1996-01-10
FI95199B (fi) 1995-09-29
AU1954588A (en) 1988-12-21
DE3851090D1 (de) 1994-09-22

Similar Documents

Publication Publication Date Title
ATE109982T1 (de) Prostaglandin-lipid-formulierungen.
Russell et al. Conversion of 3T3 fibroblasts into adipose cells: triggering of differentiation by prostaglandin F2alpha and 1-methyl-3-isobutyl xanthine.
DK98189A (da) Formuleringer af liposomale antineoplastiske midler med hoeje medikament-lipid-forhold
ATE38329T1 (de) Lungensurfactant.
AR241117A2 (es) Procedimiento para la preparacion de complejos de flavanolignanos con fosfolipidos
NO862193D0 (no) Antracyklingholdig preparater og fremgangsmaate for deres fremstilling.
NO176549C (no) Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
DK86988D0 (da) Liposompraeparat og anvendelse deraf
FR2452485B1 (fr) Nouveaux acides et esters 4-amino-3-quinoleinecarboxyliques, utiles notamment comme agents antisecretoires et anti-ulcere
FI883597A7 (fi) Menetelmä sytotoksisten aineiden kasvainsoluihin toimittamiseen käyttökelpoisen vasta-aine-entsyymikonjugaatin valmistamiseksi
FI883249A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
DE3878239D1 (de) Kristalle aus menschlichem serumalbumin und verfahren zu deren herstellung.
SE8403487D0 (sv) Farmaceutisk komposition
BG38639A3 (en) Method for preparing ester derivatives of 6- beta- hydroxymethylpenicillanic acid
TR199902025T2 (xx) Suda ileri derecede ��z�nmez olan bir etken maddeyi hapseden liyofilize lipozomlar i�eren farmas�tik preparasyon ve bu preparasyonu haz�rlamak i�in i�lem.
FI882722A7 (fi) Menetelmä 3-(bentsotiatsol-2-yylimetyyli)-4-okso-3-H-ftaaliatsin-1-yylietikkahappojohdannaisten valmistamiseksi
NO861533L (no) Griseolsyrederivater og fremgangsmaate til fremstilling derav.
EP0150710A3 (de) 7-Oxabicycloheptan-Prostaglandin-Analoge
BE884782A (fr) Nouveaux acides alcoxybenzofuranne-2-carboxyliques, leurs sels et esters, utiles notamment comme agents hypolipemiants, et leur procede de preparation
SE8303719D0 (sv) Novel eburnane oxime derivatives and process for preparing same
McClenaghan et al. Induction of a glucose-dependent insulin secretory response by the nonmetabolizable amino acid α-aminoisobutyric acid
PT87091A (pt) Process for preparing 3(5)-cyano-1h-pyrazole-4-carboxylic acid esters
DK183788A (da) Fremgangsmaade til foroegelse af levedygtigheden af frysetoerrede, maelkesyreproducerende bakteriekulturkoncentrater
BG44029A3 (en) Method for preparing of n- dimethyl morphinanic derivatives
FR2325634A1 (fr) Nouveaux esters derives d'acides 4,5-benzospiro(2,4)heptane-1-carboxyliques utiles dans la lutte contre les parasites

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee